Terms: = Pancreatic cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Staging
54 results:
1. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected pancreatic cancer.
Murthy P; Zenati MS; AlMasri SS; DeSilva A; Singhi AD; Paniccia A; Lee KK; Simmons RL; Bahary N; Lotze MT; Zureikat AH
J Natl Compr Canc Netw; 2023 Dec; 22(1D):e237070. PubMed ID: 38150819
[TBL] [Abstract] [Full Text] [Related]
2. Impact of CXCR4-Directed PET/CT on staging and Proposed Oncologic Management in Patients With Digestive System Tumors.
Weich A; Serfling SE; Schlötelburg W; Higuchi T; Hartrampf PE; Schirbel A; Heinrich M; Buck AK; Rowe SP; Kosmala A; Werner RA
Clin Nucl Med; 2023 Jul; 48(7):586-593. PubMed ID: 37167408
[TBL] [Abstract] [Full Text] [Related]
3. Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Botta GP; Huynh TR; Spierling-Bagsic SR; Agelidis A; Schaffer R; Lin R; Sigal D
Cancer Med; 2023 Apr; 12(7):7713-7723. PubMed ID: 36478411
[TBL] [Abstract] [Full Text] [Related]
4. Impact of 68 Ga-FAPI-04 PET/CT on staging and Therapeutic Management in Patients With Digestive System Tumors.
Kosmala A; Serfling SE; Schlötelburg W; Lindner T; Michalski K; Schirbel A; Higuchi T; Hartrampf PE; Buck AK; Weich A; Werner RA
Clin Nucl Med; 2023 Jan; 48(1):35-42. PubMed ID: 36354691
[TBL] [Abstract] [Full Text] [Related]
5. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of abdominal radiology disease focus panel on PDAC.
Chu LC; Wang ZJ; Kambadakone A; Hecht EM; He J; Narang AK; Laheru DA; Arif-Tiwari H; Bhosale P; Bolan CW; Brook OR; Bezuidenhout AF; Do RKG; Galgano SJ; Goenka AH; Guimaraes AR; Hough DM; Kulkarni N; Le O; Luk L; Mannelli L; Rosenthal M; Sangster G; Shah ZK; Soloff EV; Tolat PP; Zins M; Fishman EK; Tamm EP; Zaheer A
Abdom Radiol (NY); 2023 Jan; 48(1):318-339. PubMed ID: 36241752
[TBL] [Abstract] [Full Text] [Related]
6. FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Marschner N; Hegewisch-Becker S; Reiser M; von der Heyde E; Bertram M; Hollerbach SH; Kreher S; Wolf T; Binninger A; Chiabudini M; Kaiser-Osterhues A; Jänicke M;
Int J Cancer; 2023 Feb; 152(3):458-469. PubMed ID: 36053905
[TBL] [Abstract] [Full Text] [Related]
7. UNOS Down-staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies.
Tan DJH; Lim WH; Yong JN; Ng CH; Muthiah MD; Tan EX; Xiao J; Lim SY; Pin Tang AS; Pan XH; Kabir T; Bonney GK; Sundar R; Syn N; Kim BK; Dan YY; Noureddin M; Loomba R; Huang DQ
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1475-1484. PubMed ID: 35181565
[TBL] [Abstract] [Full Text] [Related]
8. Pan-cancer analysis of prognostic metastatic phenotypes.
Zaorsky NG; Wang X; Garrett SM; Lehrer EJ; Lin C; DeGraff DJ; Spratt DE; Trifiletti DM; Kishan AU; Showalter TN; Park HS; Yang JT; Chinchilli VM; Wang M
Int J Cancer; 2022 Jan; 150(1):132-141. PubMed ID: 34287840
[TBL] [Abstract] [Full Text] [Related]
9. cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
[TBL] [Abstract] [Full Text] [Related]
10. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with pancreatic Adenocarcinoma.
Yadav S; Kasi PM; Bamlet WR; Ho TP; Polley EC; Hu C; Hart SN; Rabe KG; Boddicker NJ; Gnanaolivu RD; Lee KY; Lindstrom TH; Petersen GM; Couch FJ; McWilliams RR
Clin Cancer Res; 2020 Dec; 26(24):6505-6512. PubMed ID: 33028596
[TBL] [Abstract] [Full Text] [Related]
11. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract] [Full Text] [Related]
12. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected pancreatic Ductal Adenocarcinoma.
Malleo G; Maggino L; Ferrone CR; Marchegiani G; Luchini C; Mino-Kenudson M; Paiella S; Qadan M; Scarpa A; Lillemoe KD; Bassi C; Fernàndez-Del Castillo C; Salvia R
Ann Surg Oncol; 2020 Oct; 27(10):3898-3912. PubMed ID: 32307617
[TBL] [Abstract] [Full Text] [Related]
13. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and staging of pancreatic Ductal Adenocarcinoma.
Yang Z; LaRiviere MJ; Ko J; Till JE; Christensen T; Yee SS; Black TA; Tien K; Lin A; Shen H; Bhagwat N; Herman D; Adallah A; O'Hara MH; Vollmer CM; Katona BW; Stanger BZ; Issadore D; Carpenter EL
Clin Cancer Res; 2020 Jul; 26(13):3248-3258. PubMed ID: 32299821
[TBL] [Abstract] [Full Text] [Related]
14. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME)
Nabavizadeh A; Payen T; Iuga AC; Sagalovskiy IR; Desrouilleres D; Saharkhiz N; Palermo CF; Sastra SA; Oberstein PE; Rosario V; Kluger MD; Schrope BA; Chabot JA; Olive KP; Konofagou EE
Theranostics; 2020; 10(10):4614-4626. PubMed ID: 32292518
[No Abstract] [Full Text] [Related]
15. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival.
Tella SH; Kommalapati A; Yadav S; Bergquist JR; Goyal G; Durgin L; Borad M; Cleary SP; Truty MJ; Mahipal A
Eur J Surg Oncol; 2020 May; 46(5):789-795. PubMed ID: 31954549
[TBL] [Abstract] [Full Text] [Related]
16. Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of pancreatic cancer.
Lohrmann C; O'Reilly EM; O'Donoghue JA; Pandit-Taskar N; Carrasquillo JA; Lyashchenko SK; Ruan S; Teng R; Scholz W; Maffuid PW; Lewis JS; Weber WA
Clin Cancer Res; 2019 Dec; 25(23):7014-7023. PubMed ID: 31540979
[TBL] [Abstract] [Full Text] [Related]
17. Intraoperative Near-infrared Imaging Can Identify Neoplasms and Aid in Real-time Margin Assessment During pancreatic Resection.
Newton AD; Predina JD; Shin MH; Frenzel-Sulyok LG; Vollmer CM; Drebin JA; Singhal S; Lee MK
Ann Surg; 2019 Jul; 270(1):12-20. PubMed ID: 31188797
[TBL] [Abstract] [Full Text] [Related]
18. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing.
Lee AJ; Simoneau E; Chiang YJ; Lee JE; Kim MP; Aloia TA; Vauthey JN; Katz MH; Tzeng CD
HPB (Oxford); 2019 Sep; 21(9):1203-1210. PubMed ID: 30799277
[TBL] [Abstract] [Full Text] [Related]
19. International Validation of the Eighth Edition of the American Joint Committee on cancer (AJCC) TNM staging System in Patients With Resected pancreatic cancer.
van Roessel S; Kasumova GG; Verheij J; Najarian RM; Maggino L; de Pastena M; Malleo G; Marchegiani G; Salvia R; Ng SC; de Geus SW; Lof S; Giovinazzo F; van Dam JL; Kent TS; Busch OR; van Eijck CH; Koerkamp BG; Abu Hilal M; Bassi C; Tseng JF; Besselink MG
JAMA Surg; 2018 Dec; 153(12):e183617. PubMed ID: 30285076
[TBL] [Abstract] [Full Text] [Related]
20. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma.
Swords DS; Firpo MA; Johnson KM; Boucher KM; Scaife CL; Mulvihill SJ
Surgery; 2017 Jul; 162(1):104-111. PubMed ID: 28238344
[TBL] [Abstract] [Full Text] [Related]
[Next]
